Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EOLS NASDAQ:MRSN NASDAQ:PBYI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEOLSEvolus$6.74+1.7%$5.82$3.86▼$10.20$443.86M1.341.09 million shs1.04 million shsMRSNMersana Therapeutics$29.08+0.1%$28.83$5.21▼$30.39$145.37M0.44112,909 shs712,400 shsPBYIPuma Biotechnology$7.23+0.8%$7.24$3.03▼$7.90$368M1.21339,933 shs210,071 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEOLSEvolus-1.78%-1.04%+2.00%+37.27%-33.43%MRSNMersana Therapeutics0.00%0.00%0.00%0.00%+206.19%PBYIPuma Biotechnology+1.41%+1.70%+3.61%+19.50%+107.83%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEOLSEvolus$6.74+1.7%$5.82$3.86▼$10.20$443.86M1.341.09 million shs1.04 million shsMRSNMersana Therapeutics$29.08+0.1%$28.83$5.21▼$30.39$145.37M0.44112,909 shs712,400 shsPBYIPuma Biotechnology$7.23+0.8%$7.24$3.03▼$7.90$368M1.21339,933 shs210,071 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEOLSEvolus-1.78%-1.04%+2.00%+37.27%-33.43%MRSNMersana Therapeutics0.00%0.00%0.00%0.00%+206.19%PBYIPuma Biotechnology+1.41%+1.70%+3.61%+19.50%+107.83%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEOLSEvolus 2.50Moderate Buy$16.00137.99% UpsideMRSNMersana Therapeutics 1.88Reduce$25.92-10.88% DownsidePBYIPuma Biotechnology 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest PBYI, EOLS, and MRSN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2026EOLSEvolus BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.006/15/2026EOLSEvolus Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/29/2026EOLSEvolus Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/13/2026EOLSEvolus Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/11/2026PBYIPuma Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)4/24/2026EOLSEvolus Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/21/2026PBYIPuma Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)(Data available from 6/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEOLSEvolus$301.79M1.47N/AN/A($0.36) per share-18.68MRSNMersana Therapeutics$33.18M4.38N/AN/A($1.92) per share-15.15PBYIPuma Biotechnology$227.18M1.62$0.85 per share8.47$2.59 per share2.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEOLSEvolus-$51.64M-$0.67N/A112.05N/A-14.39%N/A-19.03%8/4/2026 (Estimated)MRSNMersana Therapeutics-$69.19M-$13.88N/AN/AN/A-211.21%N/A-65.42%N/APBYIPuma Biotechnology$31.11M$0.4815.0565.68N/A10.69%20.30%12.05%8/6/2026 (Estimated)Latest PBYI, EOLS, and MRSN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026PBYIPuma Biotechnology-$0.13-$0.04+$0.09-$0.07$42.00 million$44.81 million5/4/2026Q1 2026EOLSEvolus-$0.14-$0.16-$0.02-$0.16$72.52 million$73.14 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthEOLSEvolusN/AN/AN/AN/AN/AMRSNMersana TherapeuticsN/AN/AN/AN/AN/APBYIPuma BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEOLSEvolusN/A2.041.68MRSNMersana TherapeuticsN/A1.391.39PBYIPuma BiotechnologyN/A2.382.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEOLSEvolus90.69%MRSNMersana Therapeutics93.92%PBYIPuma Biotechnology61.29%Insider OwnershipCompanyInsider OwnershipEOLSEvolus5.00%MRSNMersana Therapeutics13.00%PBYIPuma Biotechnology22.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEOLSEvolus17065.86 million62.56 millionOptionableMRSNMersana Therapeutics1505.00 million4.35 millionOptionablePBYIPuma Biotechnology20050.90 million39.60 millionOptionablePBYI, EOLS, and MRSN HeadlinesRecent News About These CompaniesPuma Biotechnology Shareholders Back Governance, Reject Warrant ExtensionJune 16 at 5:10 PM | tipranks.comPuma Biotechnology (NASDAQ:PBYI) Director Brian Stuglik Sells 8,100 SharesJune 16 at 5:00 AM | insidertrades.comPuma Biotechnology (NASDAQ:PBYI) Stock Crosses Above 200 Day Moving Average - Here's WhyJune 12, 2026 | americanbankingnews.comPuma Biotechnology Stock Rises 19% in 3 Months: Here's WhyJune 11, 2026 | zacks.comPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)June 3, 2026 | businesswire.comPuma Biotechnology Reveal Hidden Strength Amid Rising Market FocusMay 17, 2026 | kalkinemedia.comKPuma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft EarningsMay 14, 2026 | finance.yahoo.comEarnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00May 11, 2026 | finance.yahoo.comPBYI Q1 Earnings & Sales Beat Estimates, 2026 Guidance RaisedMay 8, 2026 | zacks.comPuma Biotechnology, Inc. (PBYI) Q1 2026 Earnings Call TranscriptMay 8, 2026 | seekingalpha.comPuma Biotech: Q1 Earnings SnapshotMay 8, 2026 | sfgate.comPuma Biotech (PBYI) Reports Q1 Loss, Tops Revenue EstimatesMay 7, 2026 | zacks.comPuma Biotechnology Reports First Quarter 2026 Financial ResultsMay 7, 2026 | businesswire.comPuma Biotechnology to Host Conference Call to Discuss First Quarter 2026 Financial ResultsApril 23, 2026 | finance.yahoo.comPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)April 2, 2026 | businesswire.comPuma Biotechnology Stock Declines More Than 9% in a Month: Here's WhyMarch 18, 2026 | zacks.comIRWD vs. PBYI: Which Small-Cap Biotech Stock Is a Better Buy?March 12, 2026 | zacks.comPBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 ViewFebruary 27, 2026 | zacks.comPuma Biotechnology Inc (PBYI) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic ...February 27, 2026 | finance.yahoo.comPuma anticipates $194M–$198M NERLYNX revenue for 2026 while advancing alisertib clinical programsFebruary 26, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePBYI, EOLS, and MRSN Company DescriptionsEvolus NASDAQ:EOLS$6.74 +0.11 (+1.66%) Closing price 04:00 PM EasternExtended Trading$6.74 +0.00 (+0.07%) As of 04:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.Mersana Therapeutics NASDAQ:MRSNMersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.Puma Biotechnology NASDAQ:PBYI$7.23 +0.06 (+0.84%) Closing price 04:00 PM EasternExtended Trading$7.23 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave Insider Sales Look Big, But Should Investors Worry? Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves Meta and Cloud Computing: Real Potential, or a Shot in the Dark? Gravity Check: Houston, SpaceX Has a Valuation Problem Okta’s AI Moment May Be Bigger Than Investors Realize Fox Captures The Living Room With $22B Roku Buy Dave & Buster’s Q1 Miss Raises the Stakes for Its Turnaround Plan Microsoft’s Xbox Problem Is Bigger Than a Console War Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
